Many HF patients are treated suboptimally, with hyperkalemia being one of the underlying reasons. Prof Faiez Zannad, Nancy, France, considers this clinical scenario, its consequences and how it can be managed.

Prof. Kenneth Dickstein considers the increase in potassium levels that arise as a consequence of blocking the renin-angiotensin system. Hyperkalemia is often a reason for not following guideline-recommended therapy, which underlines the need for novel potassium-lowering therapy.

Funding

This symposium was supported by an unrestricted educational grant from AstraZeneca.

In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.